ANGIO-IMAGE
ANGIO-tracer for immuno-PET imaging: a stratification and monitoring tool for anti-angiogenesis treatment
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0ANGIO-IMAGE project word cloud
Explore the words cloud of the ANGIO-IMAGE project. It provides you a very rough idea of what is the project "ANGIO-IMAGE" about.
Project "ANGIO-IMAGE" data sheet
The following table provides information about the project.
| Coordinator |
ANGIOTARGET BV
Organization address contact info |
| Coordinator Country | Netherlands [NL] |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-05-01 to 2016-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ANGIOTARGET BV | NL (AMSTERDAM) | coordinator | 50˙000.00 |
Map
Project objective
AngioTarget will introduce an angiogenesis imaging agent (ANGIO-tracer) to stratify patients prior to anti-angiogenic therapy (AAT). This proposal is focussing on colorectal cancer (CRC) and will try to save 45,000 stage II/III CRC patients from undertreatment and 60,000 stage IV patients from unnecessary treatment in Europe each year. CRC is one of the most common cancers world-wide. AAT is a widely used and promising approach to restrict growth and progression of all angiogenesis-dependent malignancies. However, this expensive anti-cancer strategy is challenged by low response rates, inadequate efficacy and resistance2. Currently, there is no tool available to stratify patients prior to AAT or monitor response to therapy. The first approved and commercially most successful anti-angiogenic drug is Avastin (Bevacizumab), accounting for over €7 billion in annual sales. As a first phase towards global acceptance of ANGIO-tracer as a standard for stratification and monitoring in AAT of cancer, AngioTarget will focus on the utility of ANGIO-tracer in determining and monitoring Avastin treatment strategies in CRC. This will ensure that all CRC patients receive optimal care and responders can benefit from AAT while non-responders are spared from ineffective treatment.
Commercial introduction in Europe of ANGIO-tracer as a stratification tool in CRC will: - Improve patient outcome by enabling optimal treatment of over 18,700 stage II/III and 14,000 stage IV patients within 5 years, reducing healthcare costs related to ineffective Avastin administration with €1.8 billion in 2024 - Increase growth and competitiveness of AngioTarget, including cumulative sales of over 261,000 units (total revenue €78 million) within 5 years and a cumulative net profit of >€30 million - Open up new markets for ANGIO-tracer (e.g. lung, prostate, breast cancer)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ANGIO-IMAGE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "ANGIO-IMAGE" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
RESHAPE (2019)
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More